EMA Authorised: Zinplava (Bezlotoxumab) — Merck Sharp & Dohme B.V.

View source ↗

Summary

EMA authorised Zinplava (bezlotoxumab) for enterocolitis, pseudomembranous colitis. Merck Sharp & Dohme B.V. is the marketing authorization holder; decision dat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pseudomembranous Colitis

Drugs mentioned

• Zinplava (bezlotoxumab)

Snippet

Status: Authorised. Therapeutic area: Enterocolitis, Pseudomembranous. MAH: Merck Sharp & Dohme B.V.. Decision date: 27/11/2025